Penn Study Finds Solid-Tumor Cancer Patients Ineligible for Clinical Trials Receive Immunotherapy at Greater Rates Despite Lack of Benefits – pennmedicine.org

PHILADELPHIA — Cancer patients who are ineligible for clinical trials receive immune checkpoint inhibitors (ICI) at greater rates than patients who are trial eligible despite no survival benefit, according to a new study by researchers at the Perelman School…

Click here to view the original article.